Nakamura, T., Ito, M., Hashimoto, J., Shinomiya, K., Asao, Y., Katsumata, K., . . . Mizunuma, H. (2015). Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis. Osteoporos Int.
Dyfyniad Arddull ChicagoNakamura, T., et al. "Clinical Efficacy and Safety of Monthly Oral Ibandronate 100 mg Versus Monthly Intravenous Ibandronate 1 mg in Japanese Patients With Primary Osteoporosis." Osteoporos Int 2015.
Dyfyniad MLANakamura, T., et al. "Clinical Efficacy and Safety of Monthly Oral Ibandronate 100 mg Versus Monthly Intravenous Ibandronate 1 mg in Japanese Patients With Primary Osteoporosis." Osteoporos Int 2015.
Rhybudd: Mae'n bosib nad yw'r dyfyniadau hyn bob amser yn 100% cywir.